Cytosorbents Corporation
CTSO
$0.78
$0.034.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.34% | 61.06% | 41.36% | 28.07% | 15.84% |
| Total Depreciation and Amortization | -20.71% | -20.65% | -20.74% | -13.78% | 39.36% |
| Total Amortization of Deferred Charges | 300.74% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -121.01% | -140.60% | -8.07% | 212.96% | 113.20% |
| Change in Net Operating Assets | 50.09% | 116.74% | -41.84% | -275.67% | -615.83% |
| Cash from Operations | 46.50% | 53.95% | 44.11% | 33.37% | 10.17% |
| Capital Expenditure | 59.68% | 13.53% | -227.14% | 47.19% | 52.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.79% | -0.97% | -13.56% | 3.29% | -5.74% |
| Cash from Investing | 63.55% | 5.85% | -54.98% | 28.52% | 32.34% |
| Total Debt Issued | -100.00% | -100.00% | -- | -- | 200.00% |
| Total Debt Repaid | 100.00% | 100.00% | -600.00% | -- | -- |
| Issuance of Common Stock | -42.93% | -45.79% | -49.44% | -98.48% | 441.75% |
| Repurchase of Common Stock | 97.33% | -20,950.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 92.66% | -- | -- | -- |
| Cash from Financing | -67.26% | -68.81% | 26.61% | -35.53% | 194.26% |
| Foreign Exchange rate Adjustments | 142.65% | 289.32% | 38.11% | 14.93% | -156.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.65% | -3,163.18% | 128.34% | 28.78% | 114.95% |